These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 5735392)

  • 1. In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine.
    Shadomy S; Shadomy HJ; McCay JA; Utz JP
    Antimicrob Agents Chemother (Bethesda); 1968; 8():452-60. PubMed ID: 5735392
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-fluorocytosine: a replacement for amphotericin B in the treatment of candida and cryptococcus neoformans infections?
    Pankey GA; Lockwood WR; Montalvo JM
    J La State Med Soc; 1970 Dec; 122(12):365-9. PubMed ID: 5492591
    [No Abstract]   [Full Text] [Related]  

  • 3. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.
    Chin CS; Cheong YM; Wong YH
    Med J Malaysia; 1989 Sep; 44(3):194-8. PubMed ID: 2696871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative in vitro study of amphotericin B 1 clotrimazole and 5-fluorocytosine against clinically isolated yeasts.
    Hamilton-Miller JM
    Sabouraudia; 1972 Nov; 10(3):276-83. PubMed ID: 4565443
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro sensitivity to amphotericin B of Cryptococcus neoformans isolated in Thailand.
    Gaew-Im M; Thasnakorn P
    J Med Assoc Thai; 1971 Jan; 54(6):405-9. PubMed ID: 5171413
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.
    Medoff G; Comfort M; Kobayashi GS
    Proc Soc Exp Biol Med; 1971 Nov; 138(2):571-4. PubMed ID: 5118468
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased susceptibility of Cryptococcus neoformans to amphotericin B in the presence of steroids.
    Mohr JA; Tatem BA; Long H; Muchmore HG; Felton FG
    Sabouraudia; 1973 Jul; 11(2):140-2. PubMed ID: 4584201
    [No Abstract]   [Full Text] [Related]  

  • 8. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
    J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097).
    Marks MI; Steer P; Eickhoff TC
    Appl Microbiol; 1971 Jul; 22(1):93-5. PubMed ID: 5165106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Letter: Meningoencephalic cryptococcosis. Presence of filamentous forms. Acquired resistance to 5 fluorocytosine and amphotericin B therapy].
    Cadoz M; Micoud M; Pasquier B; Massot C; Goullier A
    Nouv Presse Med; 1974 Oct; 3(33):2108-9. PubMed ID: 4444954
    [No Abstract]   [Full Text] [Related]  

  • 12. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU; Randhawa HS; Kowshik T; Chowdhary A; Chandy R
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses.
    Fass RJ; Perkins RL
    Ann Intern Med; 1971 Apr; 74(4):535-9. PubMed ID: 5551162
    [No Abstract]   [Full Text] [Related]  

  • 16. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).
    Medoff G; Kobayashi GS; Kwan CN; Schlessinger D; Venkov P
    Proc Natl Acad Sci U S A; 1972 Jan; 69(1):196-9. PubMed ID: 4550505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans.
    Fujita NK; Edwards JE
    Antimicrob Agents Chemother; 1981 Jan; 19(1):196-8. PubMed ID: 7018384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.